Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Keith Gottesdiener, M ...

Mistimed market entry is one of the top five reasons startups fail, writes guest author Ashish Kakran of Sierra Ventures.